Please use this identifier to cite or link to this item: https://doi.org/10.1098/rsif.2010.0715
Title: Strategies for antiviral stockpiling for future influenza pandemics: A global epidemic-economic perspective
Authors: Carrasco, L.R. 
Lee, V.J. 
Chen, M.I. 
Matchar, D.B. 
Thompson, J.P.
Cook, A.R. 
Keywords: Antiviral drugs
Epidemic modelling
Health economics
Influenza pandemic
Uncertainty
Issue Date: 7-Sep-2011
Citation: Carrasco, L.R., Lee, V.J., Chen, M.I., Matchar, D.B., Thompson, J.P., Cook, A.R. (2011-09-07). Strategies for antiviral stockpiling for future influenza pandemics: A global epidemic-economic perspective. Journal of the Royal Society Interface 8 (62) : 1307-1313. ScholarBank@NUS Repository. https://doi.org/10.1098/rsif.2010.0715
Abstract: Influenza pandemics present a global threat owing to their potential mortality and substantial economic impacts. Stockpiling antiviral drugs to manage a pandemic is an effective strategy to offset their negative impacts; however, little is known about the long-term optimal size of the stockpile under uncertainty and the characteristics of different countries. Using an epidemic-economic model we studied the effect on total mortality and costs of antiviral stockpile sizes for Brazil, China, Guatemala, India, Indonesia, New Zealand, Singapore, the UK, the USA and Zimbabwe. In the model, antivirals stockpiling considerably reduced mortality. There was greater potential avoidance of expected costs in the higher resourced countries (e.g. from $55 billion to $27 billion over a 30 year time horizon for the USA) and large avoidance of fatalities in those less resourced (e.g. from 11.4 to 2.3 million in Indonesia). Under perfect allocation, higher resourced countries should aim to store antiviral stockpiles able to cover at least 15 per cent of their population, rising to 25 per cent with 30 per cent misallocation, to minimize fatalities and economic costs. Stockpiling is estimated not to be cost-effective for two-thirds of the world's population under current antivirals pricing. Lower prices and international cooperation are necessary to make the life-saving potential of antivirals cost-effective in resource-limited countries. © 2011 The Royal Society.
Source Title: Journal of the Royal Society Interface
URI: http://scholarbank.nus.edu.sg/handle/10635/109667
ISSN: 17425689
DOI: 10.1098/rsif.2010.0715
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

21
checked on May 22, 2020

WEB OF SCIENCETM
Citations

18
checked on May 13, 2020

Page view(s)

91
checked on May 23, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.